Business Wire

CA-MULTEFIRE-ALLIANCE

19.11.2020 15:02:06 CET | Business Wire | Press release

Share
MFA Launches MulteFire 1.0 Certification Program to Support Interoperable Device Ecosystem for Private Wireless Networks

The MulteFire Alliance (MFA) today announced the launch of its MulteFire 1.0 Certification Program. In addition, the first customer premise equipment (CPE) device has been certified compliant.

With MulteFire technology, organizations can now cost-effectively deploy their own private LTE network and realize the benefits of better capacity, coverage, mobility and built-in security needed for industry 4.0 use cases.

The MulteFire 1.0 specification defines LTE operation in unlicensed and shared spectrum bands, including the global 5 GHz band. The certification program tests eNodeBs together with UEs for conformance with the MulteFire 1.0 specification to ensure an interoperable, global device ecosystem for use in unlicensed or shared radio spectrum. By removing the need for licensed spectrum, MulteFire will help to lower entry cost and accelerate high-speed, secure private wireless networking deployment.

MulteFire technology opens up an entirely new range of private wireless use cases that add to existing deployment scenarios in asset-intensive industries. New opportunities include rapid deployment situations such as field hospitals and emergency response, as well as temporary systems for pop-up events, touring, cultural and sports programs. In addition, MulteFire can also be used to complement existing private wireless deployment in licensed spectrum, for example to add capacity by tapping into the large bandwidth available in the unlicensed 5 GHz spectrum band.

“The MulteFire 1.0 Certification Program is a significant milestone for the Alliance and represents the diligent efforts of our Certification Working Group to bring this program to the industry,” said Mazen Chmaytelli, president, MFA. “We are also excited to share that we have already certified the first MulteFire radio and device solutions from Nokia as compliant.”

“By enabling private wireless connectivity in unlicensed and shared spectrum, we enable even more enterprises to deploy their own private LTE and 5G networks,” said Stephan Litjens, General Manager, Nokia Digital Automation Cloud and MFA board chair. “As a founding member of MFA, we’re firmly at the forefront of this initiative – firstly with certification of our own MulteFire CPE offering – and also to accelerate a device ecosystem for the benefit of enterprise digital transformation.”

Through overlapping membership with 3GPP, the MFA is also supporting efforts for 5G NR standalone operation in unlicensed spectrum. A recent ABI Research white paper quantifies the total addressable market size for private network equipment (for industrial manufacturing, ports, logistics, mining, and energy) in LTE and 5G at $32.37B by 2030. ABI also states that by 2030 more than half of industry verticals’ private networks using LTE or 5G will be deployed in unlicensed, shared or dedicated licensed spectrum.

DEKRA Named Authorized Test Lab for MulteFire 1.0

DEKRA , an MFA member and leader in product certification, conducted the certification testing for MulteFire 1.0 and DEKRA Malaga has been named an Authorized Test Lab for the MulteFire 1.0 Certification Program. DEKRA was already named the first Authorized Test Lab for the MulteFire 1.9 GHz sXGP Certification Program launched in Japan at the end of 2019.

“DEKRA is very pleased to continue its partnership with the MFA with the addition of MulteFire 1.0 testing to our services offering, and we are happy to contribute to the success of the MulteFire ecosystem,” said Andrés Moreno, Managing Director, DEKRA Testing and Certification Spain.

The MFA Certification Program is available to all MFA members. Upon device certification, companies will receive the ‘MulteFire Certified’ logo and certification mark for product promotion and marketing purposes. The MFA welcomes membership from all companies that have an interest in private wireless networks. To join the MFA and for more details on membership levels, visit www.multefire.org/join .

For more information on the MFA Certification Program, visit www.multefire.org/certification-program/ .

Resources:

About the MFA

The MFA is an international association dedicated to building a global ecosystem in support of the common interests of members, developers and users in the application of Long Term Evolution (LTE) and next-generation mobile cellular technology, such as 5G New Radio, in configurations that use unlicensed or shared radio spectrum. For more information about MulteFire technology, its benefits, or how to become a member of the MFA, visit www.MulteFire.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye